Digestive Diseases and Sciences

, Volume 55, Issue 12, pp 3328–3335 | Cite as

Occult Hepatitis B: Clinical Implications and Treatment Decisions

Review

Abstract

First reported in 1978, occult hepatitis B is a term used to describe the presence of hepatitis B virus (HBV) DNA without hepatitis B surface antigenemia. The prevalence of occult HBV is unclear and depends in part on the sensitivity of the hepatitis B surface antigen (HBsAg) and DNA assays used as well as the prevalence of HBV infection in the study population. The origin of occult HBV also remains in question. Several mechanisms have been hypothesized including mutations in the regulatory regions of the HBV genome, persistence of Ig-bound HBV immune complexes, viral interference, and blockage of free HBsAg secretion. Occult HBV has important clinical implications such as transmission through blood transfusion, reactivation in the setting of immunosuppression, and interference with hepatitis C treatment. To date, there is little data pertaining to the treatment of occult HBV outside of the setting of chemotherapy-induced HBV reactivation.

Keywords

Occult HBV Chronic hepatitis B HBV DNA HBs antigenemia 

References

  1. 1.
    Mulrooney-Cousins PM, Michalak TI. Persistent occult hepatitis B virus infection: Experimental findings and clinical implications. World J Gastroenterol. 2007;13(43):5682–5686.PubMedGoogle Scholar
  2. 2.
    Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol. 2004;11:18–25.CrossRefPubMedGoogle Scholar
  3. 3.
    Hoofnagle JH, Seef LB, Bales ZB, Zimmerman HJ. The type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med. 1978;298:1379–1383.CrossRefPubMedGoogle Scholar
  4. 4.
    Thiers V, Nakajima E, Kremsdorf D, et al. Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet. 1988;2:1273–1276.CrossRefPubMedGoogle Scholar
  5. 5.
    Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22–26.CrossRefPubMedGoogle Scholar
  6. 6.
    Hofer M, Joller-Jemelka H, Grob P, et al. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Eur J Clin Microbiol Infect Dis. 1998;17:6–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Shire N, Rouster S, Stanford SD, et al. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44:309–314.CrossRefPubMedGoogle Scholar
  8. 8.
    Gupta S, Singh S. Occult hepatitis B virus infection in ART-Naïve HIV-infected patients seen at a tertiary care centre in North India. BMC Infect Dis. 2010;10:1–7.CrossRefGoogle Scholar
  9. 9.
    Chevrier MC, St.-Louis M, Perreault J, et al. Detection and characterization of hepatitis B virus of anti-hepatitis core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay. Transfusion. 2007;47:1794–1802.CrossRefPubMedGoogle Scholar
  10. 10.
    Raimondo G, Navarra G, Mondello S, et al. Occult hepatitis B in liver tissue of individuals without hepatic disease. J Hepatol. 2008;48:743–746.CrossRefPubMedGoogle Scholar
  11. 11.
    Vivekanandan P, Kannangai R, Ray SC, et al. Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis. 2008;46:1227–1236.CrossRefPubMedGoogle Scholar
  12. 12.
    Weinberger K, Bauer T, Bohm S, et al. High genetic variability of the group specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J General Virol. 2000;81:1165–1174.Google Scholar
  13. 13.
    Yotsuyanagi H, Yasuda K, Iino S, et al. Persistent Viremia after recovery from self-limited acute hepatitis B. Hepatology. 1998;27:1377–1382.CrossRefPubMedGoogle Scholar
  14. 14.
    Shih CM, Lo SJ, Miyamura T, et al. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol. 1993;67:5823–5832.PubMedGoogle Scholar
  15. 15.
    Liu CJ, Chuang WL, Lee CM, et al. Peginterferon Alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136:496–504.CrossRefPubMedGoogle Scholar
  16. 16.
    Bruss V, Vieluf K. Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis. J Virol. 1995;69:6652–6657.PubMedGoogle Scholar
  17. 17.
    Chemin I, Zoulim F, Merle P, et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol. 2001;34:447–454.CrossRefPubMedGoogle Scholar
  18. 18.
    Berasain C, Betes M, Panizo A, et al. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut. 2000;47:429–435.CrossRefPubMedGoogle Scholar
  19. 19.
    Kazemi-Shirazi L, Petermann D, Muller C. Hepatitis B virus DNA in sera and liver tissue of HbsAg negative patients with chronic hepatitis C. J Hepatol. 2000;33:785–790.CrossRefPubMedGoogle Scholar
  20. 20.
    De Maria N, Colantoni A, Friedlander L, et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol. 2000;95:3529–3536.CrossRefPubMedGoogle Scholar
  21. 21.
    Fukuda R, Ishimura N, Hamamoto S, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol. 2001;63:220–227.CrossRefPubMedGoogle Scholar
  22. 22.
    Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: Old and new paradigms. Gastroenterology. 2004;127:S56–S61.CrossRefPubMedGoogle Scholar
  23. 23.
    Squadrito G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer. 2006;106:1326–1330.CrossRefPubMedGoogle Scholar
  24. 24.
    Kusakabe A, Tanaka Y, Orito E, et al. A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gasteroenterol. 2007;42:298–305.CrossRefGoogle Scholar
  25. 25.
    Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. N Engl J Med. 1996;334:1685–1690.CrossRefPubMedGoogle Scholar
  26. 26.
    Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, et al. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol. 2008;48:1022–1025.CrossRefPubMedGoogle Scholar
  27. 27.
    Mas A. Liver transplantation for hepatitis B virus. Pre-emptive and peri-operative prophylaxis. Dig Liver Dis. 2009;41S:S191–S194.CrossRefGoogle Scholar
  28. 28.
    Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: A survey of North American, European, and Asian-Pacific transplant programs. Liver Transplantation. 2009;15:223–232.CrossRefPubMedGoogle Scholar
  29. 29.
    Ghisetti V, Marzano A, Zamboni F, et al. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: Clinical significance. Liver Transplant. 2004;10:356–362.CrossRefGoogle Scholar
  30. 30.
    Roche B, Samuel D, Gigou M, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol. 1997;26:517–526.CrossRefPubMedGoogle Scholar
  31. 31.
    Galbraith RM, Eddleston AL, Williams R, et al. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet. 1975;2:528–530.CrossRefPubMedGoogle Scholar
  32. 32.
    Lalazar G, Rund D, Shouval D, et al. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Hematol. 2007;136:699–712.CrossRefGoogle Scholar
  33. 33.
    Hsu C, Hsiung CA, Su I, et al. A revisit of prophylactic Lamivudine for chemotherapy-associated hepatitis B reactivation in Non-Hodgkin’s lymphoma: A randomized trial. Hepatology. 2008;47:844–853.CrossRefPubMedGoogle Scholar
  34. 34.
    Hui C, Cheung W, Zhang H, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.CrossRefPubMedGoogle Scholar
  35. 35.
    Meeting report. The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting. J Clin Virol. 2008;41:243–254.Google Scholar
  36. 36.
    Keefe E, Dieterich D, Han S, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clinical Gastroenterology and Hepatology. 2008;6:1315–1341.CrossRefGoogle Scholar
  37. 37.
    Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47:760–767.CrossRefPubMedGoogle Scholar
  38. 38.
    Fung J, Lai C-L, But D, et al. Prevalence of fibrosis and cirrhosis in chronic hepatitis B: Implications for treatment and management. Am J Gastroenterol. 2008;103:1421–1426.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Digestive DiseasesUniversity of Cincinnati College of MedicineCincinnatiUSA

Personalised recommendations